Cyclodextrins fighting GOUT

I remember that I already loved the topic when Adrián Matencio Durán first told me about it in 2022.

Now the paper is out, summarizing the key results:
1. First-time use of CDs and CD-polymers (HBCD-Pol) as a novel strategy to treat gout and hyperuricemia.

2. HBCD-Pol shows superior uric acid solubilization compared to native cyclodextrins.

3. In vitro tests confirm inhibition and dissolution of MSU crystal formation.

4. In vivo studies show reduced inflammation and cytokine modulation without toxicity.

5. CDs and HBCD-Pol offer a safe, effective platform for UA-related disease therapy.

I trust to see some in vivo data soon. Will I?

Commercial and non-commercial cyclodextrin derivatives as a novel therapy to improve gout’s disease and hyperuricemia – ScienceDirect